Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Loss Narrows At MedImmune; Serono's Profits Still Climbing

Oct. 24, 2003

By Aaron Lorenzo

Loss Narrows At MedImmune; Serono's Profits Still Climbing

Oct. 24, 2003

By Aaron Lorenzo

AaiPharma Purchases Four Pain Products From Elan For $100M

Oct. 23, 2003

By Aaron Lorenzo

AaiPharma Purchases Four Pain Products From Elan For $100M

Oct. 23, 2003

By Aaron Lorenzo

Biospect Raises $27M In Series A Round; Diagnostics First Focus

Oct. 22, 2003

By Aaron Lorenzo

Biospect Raises $27M In Series A Round; Diagnostics First Focus

Oct. 22, 2003

By Aaron Lorenzo

Next Up: Renovis Steps Into Growing Biotech IPO Queue

Oct. 21, 2003

By Aaron Lorenzo

Next Up: Renovis Steps Into Growing Biotech IPO Queue

Oct. 21, 2003

By Aaron Lorenzo

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Oct. 20, 2003

By Aaron Lorenzo

Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today)

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Oct. 20, 2003

By Aaron Lorenzo

Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today)

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...